UNSPSC 41131722: Heparin assay

In this classification a heparin assay is a device used to determine the level of the anticoagulant heparin in the patient's circulation. These assays are quantitative clotting time procedures using the effect of heparin on activated coagulation factor X (Stuart factor) or procedures based on the neutralization of heparin by protamine sulfate (a protein that neutralizes heparin) US FDA regulates Heparin assay under 21 CFR 864.7525 and under FDA product code KFF.

UNSPSC 41131722 Heparin assay is a Commodity code covering drug-screening and forensic-laboratory testing supplies, reagents, and assay kits used by state agencies, counties, cities, and public health systems. Recent solicitations under this code reflect broader state and local demand for specimen collection, immunoassay and confirmatory testing platforms, drug standards, and laboratory consumables supporting criminal justice, occupational health, and clinical diagnostics. Collin County Community Supervision and Corrections Department's RFP for offender specimen collection and drug testing services (RFP 2026-327, due July 23, 2026, estimated value $600,000 annually) exemplifies the scope—immunoassay screening with LC/MS/MS or GC/MS confirmation, interactive voice response systems for random testing notifications, and alternative methodologies including oral fluid and hair testing. The Texas Comptroller of Public Accounts' IFB for proprietary chemical laboratory equipment and supplies (304T-27-175A1.1, due October 20, 2026) itemizes specialized DNA analysis and drug-screening reagents compatible with Applied Biosystems and SeqStudio genetic analyzers, with products from Life Technologies Corp., Promega, Qiagen, Immunalysis Corporation, and ANDE Corporation. Issuing bodies include county community corrections and health departments, municipal police and safety agencies, state criminal justice and public health departments, universities, and specialized forensic laboratories. Collin County has posted multiple opportunities (offender testing and general laboratory services), and Texas state procurement has centralized drug-testing supply procurement.

Geographic activity concentrates in Texas (Collin County and state-level procurement), Georgia (Gwinnett County's drugs-of-abuse analyzer supplies, due October 14, 2026), Florida (Seminole County naloxone and drug deactivation systems; Pinellas County forensic drug standards funded by the Paul Coverdell Act, due April 23, 2026), Oregon (Benton County urinalysis testing, due July 7, 2026; Oregon Health Authority clozapine assay kit sole source, due May 11, 2026), and North Carolina (Charlotte drug and alcohol testing services, due October 12, 2026). Additional activity spans Wisconsin (University of Wisconsin-Madison blood draw kits, due August 3, 2026) and New Mexico (Bernalillo County occupational health services including drug screening, due October 8, 2026). Recent opportunities are weighted toward criminal-justice and occupational-health testing, with forensic and clinical laboratory supply procurement running concurrently. Pricing models vary—per-test models in criminal justice (Collin County structured screening, confirmation, and combined pricing), fixed-term supply agreements (Texas state statewide delivery with firm pricing through October 31, 2027), and unit-cost quotes (Pinellas County drug standards under federal Paul Coverdell funding). Lab certification requirements (SAMHSA, CLIA, CAP, ISO/IEC 17025) and storage/handling compliance (2–8 degrees Celsius, shelf-life tracking, replacement warranties) are consistent across solicitations.